| UniProt ID | ISCU_HUMAN | |
|---|---|---|
| UniProt AC | Q9H1K1 | |
| Protein Name | Iron-sulfur cluster assembly enzyme ISCU, mitochondrial | |
| Gene Name | ISCU | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 167 | |
| Subcellular Localization |
Isoform 1: Mitochondrion . Isoform 2: Cytoplasm. Nucleus . |
|
| Protein Description | Scaffold protein for the de novo synthesis of iron-sulfur (Fe-S) clusters within mitochondria, which is required for maturation of both mitochondrial and cytoplasmic [2Fe-2S] and [4Fe-4S] proteins. [PubMed: 11060020 First, a [2Fe-2S] cluster is transiently assembled on the scaffold protein ISCU. In a second step, the cluster is released from ISCU, transferred to a glutaredoxin GLRX5, followed by the formation of mitochondrial [2Fe-2S] proteins, the synthesis of [4Fe-4S] clusters and their target-specific insertion into the recipient apoproteins. Cluster assembly on ISCU depends on the function of the cysteine desulfurase complex NFS1-LYRM4/ISD11, which serves as the sulfur donor for cluster synthesis, the iron-binding protein frataxin as the putative iron donor, and the electron transfer chain comprised of ferredoxin reductase and ferredoxin, which receive their electrons from NADH (By similarity] | |
| Protein Sequence | MAAAGAFRLRRAASALLLRSPRLPARELSAPARLYHKKVVDHYENPRNVGSLDKTSKNVGTGLVGAPACGDVMKLQIQVDEKGKIVDARFKTFGCGSAIASSSLATEWVKGKTVEEALTIKNTDIAKELCLPPVKLHCSMLAEDAIKAALADYKLKQEPKKGEAEKK | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 7 (in isoform 2) | Phosphorylation | - | 8.06 | 25404012 | |
| 11 (in isoform 2) | Phosphorylation | - | 38.81 | 20068231 | |
| 12 (in isoform 2) | Phosphorylation | - | 10.19 | 20068231 | |
| 14 | Phosphorylation | FRLRRAASALLLRSP HHHHHHHHHHHHCCC | 20.61 | 19664994 | |
| 18 (in isoform 2) | Phosphorylation | - | 5.46 | 20068231 | |
| 20 | Phosphorylation | ASALLLRSPRLPARE HHHHHHCCCCCCHHH | 17.84 | 26055452 | |
| 29 | Phosphorylation | RLPARELSAPARLYH CCCHHHHCCCCHHHC | 27.70 | 30266825 | |
| 29 (in isoform 2) | Ubiquitination | - | 27.70 | 21890473 | |
| 32 (in isoform 2) | Ubiquitination | - | 17.52 | 21890473 | |
| 43 | Phosphorylation | HKKVVDHYENPRNVG CHHHHCCCCCCCCCC | 16.97 | 25884760 | |
| 51 | Phosphorylation | ENPRNVGSLDKTSKN CCCCCCCCCCCCCCC | 29.16 | - | |
| 54 | Ubiquitination | RNVGSLDKTSKNVGT CCCCCCCCCCCCCCC | 61.05 | 21890473 | |
| 54 (in isoform 1) | Ubiquitination | - | 61.05 | 21890473 | |
| 57 (in isoform 2) | Ubiquitination | - | 61.97 | 21890473 | |
| 57 | Ubiquitination | GSLDKTSKNVGTGLV CCCCCCCCCCCCCCC | 61.97 | 21890473 | |
| 57 (in isoform 1) | Ubiquitination | - | 61.97 | 21890473 | |
| 66 (in isoform 2) | Ubiquitination | - | 4.88 | 21890473 | |
| 69 | Glutathionylation | GLVGAPACGDVMKLQ CCCCCCCCCCEEEEE | 4.68 | 22555962 | |
| 73 | Sulfoxidation | APACGDVMKLQIQVD CCCCCCEEEEEEEEC | 4.22 | 21406390 | |
| 82 (in isoform 1) | Ubiquitination | - | 62.13 | 21890473 | |
| 82 | Ubiquitination | LQIQVDEKGKIVDAR EEEEECCCCCEEEEE | 62.13 | 21890473 | |
| 82 | 2-Hydroxyisobutyrylation | LQIQVDEKGKIVDAR EEEEECCCCCEEEEE | 62.13 | - | |
| 87 (in isoform 2) | Ubiquitination | - | 35.18 | 21890473 | |
| 91 (in isoform 1) | Ubiquitination | - | 37.07 | 21890473 | |
| 91 | Ubiquitination | KIVDARFKTFGCGSA CEEEEEEEEECCCHH | 37.07 | 21890473 | |
| 92 | Phosphorylation | IVDARFKTFGCGSAI EEEEEEEEECCCHHH | 23.65 | 21406692 | |
| 96 (in isoform 2) | Ubiquitination | - | 22.08 | 21890473 | |
| 97 | Phosphorylation | FKTFGCGSAIASSSL EEEECCCHHHHCCHH | 22.15 | 18669648 | |
| 101 | Phosphorylation | GCGSAIASSSLATEW CCCHHHHCCHHCHHH | 17.85 | 18669648 | |
| 102 | Phosphorylation | CGSAIASSSLATEWV CCHHHHCCHHCHHHH | 21.98 | 18669648 | |
| 103 | Phosphorylation | GSAIASSSLATEWVK CHHHHCCHHCHHHHC | 21.37 | 21406692 | |
| 106 | Phosphorylation | IASSSLATEWVKGKT HHCCHHCHHHHCCCC | 35.36 | 21406692 | |
| 112 | Ubiquitination | ATEWVKGKTVEEALT CHHHHCCCCHHHHHH | 43.62 | 21890473 | |
| 112 (in isoform 1) | Ubiquitination | - | 43.62 | 21890473 | |
| 121 | Ubiquitination | VEEALTIKNTDIAKE HHHHHHCCCCHHHHH | 48.86 | 21890473 | |
| 121 (in isoform 1) | Ubiquitination | - | 48.86 | 21890473 | |
| 122 (in isoform 2) | Ubiquitination | - | 38.85 | 21890473 | |
| 127 | Acetylation | IKNTDIAKELCLPPV CCCCHHHHHHCCCCC | 52.10 | 25038526 | |
| 147 | Ubiquitination | MLAEDAIKAALADYK HHHHHHHHHHHHHHH | 29.36 | 21890473 | |
| 147 (in isoform 1) | Ubiquitination | - | 29.36 | 21890473 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
| 14 | S | Phosphorylation | Kinase | MTOR | P42345 | PSP |
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of ISCU_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of ISCU_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| NUP62_HUMAN | NUP62 | physical | 25416956 | |
| NECA2_HUMAN | NECAB2 | physical | 25416956 | |
| BANP_HUMAN | BANP | physical | 25416956 | |
| ATRAP_HUMAN | AGTRAP | physical | 25416956 | |
| LNX1_HUMAN | LNX1 | physical | 25416956 | |
| K1C40_HUMAN | KRT40 | physical | 25416956 | |
| FAM9B_HUMAN | FAM9B | physical | 25416956 | |
| CC172_HUMAN | CCDC172 | physical | 25416956 | |
| HSC20_HUMAN | HSCB | physical | 24573684 | |
| NFS1_HUMAN | NFS1 | physical | 24573684 | |
| NECA2_HUMAN | NECAB2 | physical | 21516116 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| OMIM Disease | ||||||
| 255125 | Myopathy with exercise intolerance Swedish type (MEIS) | |||||
| Kegg Drug | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Phosphorylation | |
| Reference | PubMed |
| "Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14, VARIANT VAL-12, ANDMASS SPECTROMETRY. | |
| "Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14, AND MASSSPECTROMETRY. | |
| "A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14, AND MASSSPECTROMETRY. | |